SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS

Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are oral antidiabetic agents commonly used for the treatment of type 2 diabetes mellitus. More than ten years of clinical experience with this group of drugs provides evidence of their efficacy and good tolerability especially in patients at ris...

Full description

Bibliographic Details
Main Author:	M. Ganeva
Format:	Article
Language:	English
Published:	Trakia University 2023-03-01
Series:	Trakia Journal of Sciences
Subjects:	: dipeptidyl peptidase-4 inhibitors diabetes mellitus adverse reaction
Online Access:	http://tru.uni-sz.bg/tsj/Volume%2021,%202023,%20Number%201,%20Series%20Biomedical%20Sciences/9_M.Ganeva.pdf

Similar Items

Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
by: Eugene Yu-Chuan Kang, et al.
Published: (2021-06-01)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

The influence of dipeptidyl peptidase-4 inhibitor on the progression of type B intramural hematoma
by: Qu Chen, et al.
Published: (2022-10-01)

Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
by: E V Oskola, et al.
Published: (2013-09-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
by: Akifumi Matsumoto, et al.
Published: (2023-12-01)

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
by: Maneesha Khalse, et al.
Published: (2018-01-01)

Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus
by: Takeshi Hasegawa, et al.
Published: (2021-04-01)

Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
by: Rodrigo Daza-Arnedo, et al.
Published: (2021-11-01)

Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus
by: Jie Meng, et al.
Published: (2023-12-01)

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
by: Chia-Yu Chang, et al.
Published: (2017-12-01)

Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
by: Xin Wei, et al.
Published: (2021-08-01)

Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
by: A S Ametov, et al.
Published: (2014-08-01)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
by: Choi YJ, et al.
Published: (2019-08-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020-09-01)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
by: Yasutake Shinohara, et al.
Published: (2020-10-01)

The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease
by: Usha ePanchapakesan, et al.
Published: (2015-08-01)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
by: Dan-Dan Qiu, et al.
Published: (2018-01-01)

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan
by: Sodai Kubota, et al.
Published: (2023-01-01)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
by: Wang N, et al.
Published: (2019-08-01)

Dipeptidyl peptidase 4 inhibitors in modern domestic practice
by: A. S. Ametov, et al.
Published: (2020-05-01)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
by: Vaia Lambadiari, et al.
Published: (2021-02-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus
by: Elisabetta Bigagli, et al.
Published: (2020-03-01)

A haplotype in the dipeptidyl peptidase 4 gene impacts glycemic-related traits of Brazilian older adults
by: E.S. Alves, et al.
Published: (2022-10-01)

A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
by: Sibhghatulla Shaikh, et al.
Published: (2021-06-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
by: Shen-Chih Wang, et al.
Published: (2022-03-01)

Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
by: Mee Kyoung Kim, et al.
Published: (2023-08-01)

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Shusuke Yagi, et al.
Published: (2015-08-01)

Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
by: Ilaria Barchetta, et al.
Published: (2022-09-01)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
by: Ikuko Shibasaki, et al.
Published: (2022-07-01)

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
by: Dan Liu, et al.
Published: (2019-03-01)

Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al.

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
by: Jung Min Lee, et al.
Published: (2019-10-01)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
by: Lin YH, et al.
Published: (2019-12-01)

Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
by: Jie Huang, et al.
Published: (2022-03-01)

Rurality is associated with lower likelihood of dipeptidyl peptidase 4 inhibitor use for treatment intensification
by: Danielle K. Nagy, et al.
Published: (2024-03-01)

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees
by: Ji Yeon Lee, et al.
Published: (2017-09-01)